Cowen analyst Max Masucci upgraded PerkinElmer to Outperform from Market Perform with a price target of $164, down from $192. Following three years of effective "COVID cash" generation and divestitures, the go-forward organization is capable of outperforming consensus growth and profitability expectations through fiscal 2025, Masucci tells investors in a research note. The analyst has increased confidence around the stability and growth within PerkinElmer’s newborn-screening business, and sees scope for upside in both the U.S. and internationally.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PKI:
